The Atriva Company
Founded in 2015, Atriva Therapeutics is a biopharmaceutical company specifically pioneering the development of host-targeting antiviral therapies set up by a team of leading scientists in viral research and seasoned industry experts. The company aims to develop new antiviral therapies against different severe respiratory viral infections with a high unmet medical need, such as influenza and COVID-19.
Atriva’s lead product zapnometinib (INN, previously known as ATR-002) is a first-in-class host-targeting agent which inhibits viral replication in influenza and favorably modulates the body’s immune response. Zapnometinib has successfully completed a Phase I trial to demonstrate safety and tolerability in healthy subjects (NCT04385420). A Phase II study to evaluate efficacy in hospitalized COVID-19 patients obtained approval from German drug authority (BfArM). The first patient was enrolled in April 2021 (NCT04776044). A clinical Phase II study in influenza is currently planned, as are further Phase II and III studies in COVID-19.
Due to its mechanism of action offering a dual benefit – antiviral activity and immunomodulation – zapnometinib is uniquely positioned as a promising therapeutic candidate which holds strong potential in the current COVID-19 pandemic and beyond. The small molecule could prevent a cytokine storm and the associated progression to a life-threatening disease in patients with COVID-19. Treating moderately to severely ill patients aims to reduce the number of critically sick people, which would otherwise be referred to ICUs and require more invasive treatment options. This could fundamentally impact COVID-19 outcomes and can be vital for national health systems, patients and families.
Atriva Therapeutics owns eleven patent families with broad international coverage related to the use of MEK inhibitors and other kinase inhibitors for anti-viral therapies. The patent life runs through 2041. The company is located in Frankfurt/Main and Tübingen, Germany.